ArticleCureus2026
Severe Euglycemic Ketoacidosis Secondary to Tirzepatide Use for Weight Loss.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous reports have documented the incidence of euglycemic ketoacidosis as a complication of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. However, euglycemic ketoacidosis secondary to the use of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists, such as tirzepatide, is becoming increasingly prevalent. While cases of euglycemic ketoacidosis in patients using tirzepatide managed with intravenous dextrose have been reported, this case describes a unique and severe presentation. We report a case of starvation-induced euglycemic ketoacidosis secondary to tirzepatide use resulting in transient neurological deficits, profound metabolic acidosis, and acute renal failure requiring intensive care admission and continuous renal replacement therapy. This report highlights the diagnostic challenges in patients presenting with altered levels of consciousness and an unclear clinical history, emphasizing the need for a high index of suspicion for ketoacidosis in patients on tirzepatide, even in the presence of normal blood glucose levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.